ImmunoACT is a pioneering cell and gene therapy company, established in 2018 as a spin-off from the Biosciences & Bioengineering department at IIT Bombay. Incubated at SINE (Society for Innovation and Entrepreneurship), our journey began with a singular mission: to make life-saving gene-modified cell therapies accessible and affordable for patients battling aggressive cancers and clinically unmet disorders.
Rooted in research dating back to 2013, ImmunoACT today stands as a fully integrated cell and gene therapy company, backed by a state-of-the-art, cGMP-compliant manufacturing facility that adheres to the highest global standards. From discovery to development, clinical validation to commercialization — we control the entire value chain to ensure quality, consistency, and scalability.
Our cancer immunotherapies are designed to reprogram a patient’s own immune system to recognize and destroy cancer cells — restoring its natural ability to fight disease. These are precision-engineered, single-dose treatments intended to deliver deep, lasting responses in otherwise refractory conditions.
Developing gene-modified cell therapies is inherently complex, requiring years of R&D, rigorous clinical trials, and specialized infrastructure. Despite this, our unwavering goal remains clear: to democratize access to these breakthrough therapies by dramatically lowering their cost and expanding their reach.
